| 0.698 Data as of May 17 | +0.078 / +12.58%Today’s Change | 0.43 Today|||52-Week Range 0.99 | +24.64% Year-to-Date |
| SECTOR Producer Manufacturing | INDUSTRY Industrial Machinery | MARKET CAP $88.2M |
Company Description
Provectus Pharmaceuticals, Inc. is a development-stage biopharmaceutical company, which specializes in developing oncology and dermatology therapies. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The company's dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed its Phase 2 trials of PV-10 and of PH-10. The company was founded on May 1, 1978 and is headquartered in Knoxville, TN.
Employees

Shareholders
| Individual stakeholders | 13.72% |
| Other institutional | 0.69% |
| Mutual fund holders | 0.62% |
Top Executives
| H. Craig Dees, PhD | Chairman & Chief Executive Officer |
| Timothy C. Scott, PhD | President & Director |
| Peter R. Culpepper, MBA, CPA | COO, CFO, Secretary & Treasurer |
| Eric A. Wachter, PhD | Chief Technology Officer |